Baxter International (BAX)
(Delayed Data from NYSE)
$36.02 USD
+0.51 (1.44%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $36.02 0.00 (0.00%) 5:28 PM ET
4-Sell of 5 4
B Value C Growth B Momentum B VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
Net Sales: Acute Therapies [$M] |
-- | 770 | 735 | 782 | 740 | 535 |
Net Sales: Other [$M] |
-- | 87 | 177 | 109 | 105 | 485 |
Net Sales: Kidney Care [$M] |
-- | 4,453 | 4,449 | -- | -- | -- |
Net Sales: Infusion Therapies and... |
-- | 3,960 | 3,817 | -- | -- | -- |
Net Sales: Advanced Surgery [$M] |
-- | 1,051 | 998 | 977 | 886 | 877 |
Net Sales: Medical Products and T... |
-- | 5,011 | 4,815 | -- | -- | -- |
Net Sales: Care and Connectivity ... |
-- | 1,800 | 1,791 | -- | -- | -- |
Net Sales: Front Line Care [$M] |
-- | 1,213 | 1,148 | 70 | -- | -- |
Net Sales: Healthcare Systems and... |
-- | 3,013 | 2,939 | -- | -- | -- |
Net Sales: Injectables and Anesth... |
-- | 1,347 | 1,305 | -- | -- | -- |
Net Sales: Drug Compounding [$M] |
-- | 902 | 821 | -- | -- | -- |
Net Sales: Pharmaceuticals [$M] |
-- | 2,249 | 2,126 | 2,291 | 2,098 | 2,155 |
Net Sales: Chronic Therapies [$M] |
-- | 3,683 | 3,714 | -- | -- | -- |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Net Sales: Acute Therapies: Inter... |
-- | 499 | 472 | 495 | 454 | 351 |
Net Sales: Pharmaceuticals: Inter... |
-- | 1,490 | 1,444 | 1,538 | 1,249 | 1,215 |
Net Sales: Advanced Surgery: Inte... |
-- | 469 | 424 | 432 | 370 | 342 |
Net Sales: Other: U.S. [$M] |
-- | 66 | 137 | 81 | 77 | 234 |
Net Sales: Other: International [... |
-- | 21 | 40 | 28 | 28 | 251 |
Net Sales: Front Line Care: Inter... |
-- | 308 | 308 | 19 | -- | -- |
Net Sales: Kidney Care: U.S. [$M] |
-- | 1,198 | 1,186 | -- | -- | -- |
Net Sales: Infusion Therapies and... |
-- | 1,733 | 1,576 | -- | -- | -- |
Net Sales: Medical Products and T... |
-- | 2,202 | 2,000 | -- | -- | -- |
Net Sales: Care and Connectivity ... |
-- | 537 | 496 | -- | -- | -- |
Net Sales: Healthcare Systems and... |
-- | 845 | 804 | -- | -- | -- |
Net Sales: Injectables and Anesth... |
-- | 588 | 623 | -- | -- | -- |
Net Sales: Drug Compounding: Inte... |
-- | 902 | 821 | -- | -- | -- |
Net Sales: Chronic Therapies: Int... |
-- | 2,756 | 2,791 | -- | -- | -- |
Net Sales: Kidney Care: Internati... |
-- | 3,255 | 3,263 | -- | -- | -- |
Geographic Net Sales: United Stat... |
-- | 7,000 | 6,955 | 5,180 | 4,878 | 4,826 |
Geographic Net Sales: Internation... |
-- | 7,813 | 7,551 | 7,604 | 6,795 | 6,536 |
Net Sales: Infusion Therapies and... |
-- | 2,227 | 2,241 | -- | -- | -- |
Net Sales: Advanced Surgery: U.S.... |
-- | 582 | 574 | 545 | 516 | 535 |
Net Sales: Medical Products and T... |
-- | 2,809 | 2,815 | -- | -- | -- |
Net Sales: Care and Connectivity ... |
-- | 1,263 | 1,295 | -- | -- | -- |
Net Sales: Front Line Care: U.S. ... |
-- | 905 | 840 | 51 | -- | -- |
Net Sales: Healthcare Systems and... |
-- | 2,168 | 2,135 | -- | -- | -- |
Net Sales: Injectables and Anesth... |
-- | 759 | 682 | -- | -- | -- |
Net Sales: Pharmaceuticals: U.S. ... |
-- | 759 | 682 | 753 | 849 | 940 |
Net Sales: Chronic Therapies: U.S... |
-- | 927 | 923 | -- | -- | -- |
Net Sales: Acute Therapies: U.S. ... |
-- | 271 | 263 | 287 | 286 | 184 |
Income - Line of Business | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Operating income (loss): Medical ... |
-- | 972 | 962 | -- | -- | -- |
Operating income (loss): Healthca... |
-- | 483 | 494 | -- | -- | -- |
Operating income (loss): Pharmace... |
-- | 401 | 391 | -- | -- | -- |
Operating income (loss): Kidney C... |
-- | 300 | 408 | -- | -- | -- |
Operating income (loss): Other [$... |
-- | 18 | 77 | -- | -- | -- |